Clinical Trials Browser

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT03175432 2025-11-03

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Phase 2 Active not recruiting

29 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03202940 2025-09-25

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

Phase 1/2 Active not recruiting

16 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04079179 2025-09-18

NACHO-COBI

Phase 2 Recruiting

90 enrolled

MyeloidSarcoma

Histiocytosis, Langerhans-Cell, Xanthogranuloma, Juvenile, Histiocytosis, Sinus, Histiocytic Disorders, Malignant, Erdheim-Chester Disease, Histiocytic Sarcoma

NCT05441514 2025-09-16

Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Active not recruiting

3 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

300 enrolled

Tumor-Agnostic

Neoplasms

NCT03108131 2025-05-28

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Phase 2 Completed

49 enrolled 10 charts

Adenocarcinoma, Mucinous, Neoplasm Metastasis, Neoplasms

NCT02902029 2025-04-09

ImmunoCobiVem

Phase 2 Completed

186 enrolled

Dermatologic

Melanoma

Clinical Trials

TAPUR

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

CONCERTO

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

DETERMINE